Skip to main content

Main menu

  • Home
  • Content
    • Early Access
    • Current Issue
    • Kidney360 Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Clinical Images
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • More
    • About Kidney360
    • Advertising
    • Disqus Commenting
    • Email Alerts
    • Feedback
    • Reprint Information
  • ASN Kidney News
  • Other
    • JASN
    • CJASN
    • Kidney News Online
    • American Society of Nephrology

User menu

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • CJASN
    • Kidney News Online
    • American Society of Nephrology
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Early Access
    • Current Issue
    • Kidney360 Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Clinical Images
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • More
    • About Kidney360
    • Advertising
    • Disqus Commenting
    • Email Alerts
    • Feedback
    • Reprint Information
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow Kidney360 on Twitter
  • Community Forum
  • Kidney360 RSS
Review Articles

The Effectiveness of Depression Treatment for Adults with ESKD: A Systematic Review

Pavan Chopra, Chelsea K. Ayers, Jennifer R. Antick, Devan Kansagara and Karli Kondo
Kidney360 March 2021, 2 (3) 558-585; DOI: https://doi.org/10.34067/KID.0003142020
Pavan Chopra
1Department of Medicine, Oregon Health and Science University, Portland, Oregon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chelsea K. Ayers
2Evidence Synthesis Program, Veterans Affairs Portland Health Care System, Portland, Oregon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer R. Antick
3School of Graduate Psychology, Pacific University, Hillsboro, Oregon
4Legacy Good Samaritan Medical Center, Portland, Oregon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Devan Kansagara
1Department of Medicine, Oregon Health and Science University, Portland, Oregon
2Evidence Synthesis Program, Veterans Affairs Portland Health Care System, Portland, Oregon
5Center to Improve Veteran Involvement in Care, Veterans Affairs Portland Health Care System, Portland, Oregon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karli Kondo
2Evidence Synthesis Program, Veterans Affairs Portland Health Care System, Portland, Oregon
6Research Integrity Office, Oregon Health and Science University, Portland, Oregon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Karli Kondo
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Adults with dialysis-dependent ESKD experience higher rates of depression than the general population, yet efficacy of depression treatments in this population is not well understood. We conducted a systematic review of the benefits and harms of depression treatment in adults with ESKD. We searched multiple data sources through June 2020 for English-language, controlled trials that compared interventions for depression in adults with ESKD to another intervention, placebo, or usual care, and reported depression treatment–related outcomes. Observational studies were included for harms. Two investigators independently screened all studies using prespecified criteria. One reviewer abstracted data on study design, interventions, implementation characteristics, and outcomes, and a second reviewer provided confirmation. Two reviewers independently assessed study quality and resolved any discords through discussion or a third reviewer. Strength of evidence (SOE) was assessed and agreed upon by review-team consensus. We qualitatively analyzed the data and present syntheses in text and tables. We included 26 RCTs and three observational studies. SSRIs were the most studied type of drug and the evidence was largely insufficient. We found moderate SOE that long-term, high-dose vitamin D3 is ineffective for reducing depression severity. Cognitive behavioral therapy is more effective than (undefined) psychotherapy and placebo for depression improvement and quality of life (low SOE), and acupressure is more effective than usual care or sham acupressure in reducing depression severity (low SOE). There is limited research evaluating treatment for depression in adults with ESKD, and existing studies may not be generalizable to adults in the United States. Studies suffer from limitations related to methodologic quality or reporting. More research replicating studies of promising interventions in US populations, with larger samples, is needed.

Systematic Review registry name and registration number: PROSPERO, CRD42020140227

  • clinical nephrology
  • depression
  • depression treatment
  • ESKD
  • ESRD
  • systematic review

Introduction

The incidence and prevalence of ESKD in the United States have increased steadily over the past four decades (1). Psychiatric and mental-health disorders are more common in adults with ESKD, and include issues such as depression, dementia, delirium, substance abuse, psychoses, anxiety, and personality disorders (2⇓–4). Adults with ESKD experience major depressive disorder at anywhere from three to over six times that of the general US population, depending on the method of assessment, and depression is the most common mental-health issue in this population (5,6).

The effect of depression can be extremely detrimental for a wide range of patient outcomes for those with ESKD. For instance, adults with ESKD who have depressive symptoms have a 12% higher rate of hospitalization than those without (7), and those with ESKD and psychiatric issues have a 40%–50% increased risk of all-cause mortality (8). Comorbid depression is associated with increased emergency-department visits, hospitalizations, hospital length of stay, suicide, and treatment nonadherence, along with decreased quality of life (QoL) and sleep (8⇓⇓⇓⇓–13).

There are no established guidelines for treating depression in adults with ESKD. Less than 25% of those on dialysis who are diagnosed with moderate or severe depression actually undergo treatment (12,14,15). There are few studies of treatment efficacy in this population and, while some studies include only participants with clinical depression, others include any adults with ESKD. Psychosocial treatments and cognitive behavioral therapy (CBT) are commonly used; however, interventions vary widely, the evidence is limited, and findings may vary on the basis of the presence and severity of depression.

Given the wide variation in depression treatment options for adults with ESKD, it is vital to understand the depression treatment–related outcomes for those in this population suffering from clinical depression. The purpose of this review is to better understand the benefits and harms of treatment for depression in these adults.

Materials and Methods

Topic Development

This systematic review was part of a larger review commissioned by the Veterans Health Administration (VHA) (16). A protocol describing the review plan was posted to PROSPERO, a systematic review registry, before study initiation (CRD42020140227). Our methods and reporting follow Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (17). See Supplemental Table 1 for the scope and parameters of the systematic review.

Data Sources and Searches

To identify trials examining the treatment of depression in adults with ESKD, we searched Ovid MEDLINE, PsycINFO, Elsevier EMBASE, and the Ovid Evidence-Based Medicine Reviews (Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Health Technology Assessment, Cochrane CENTRAL, etc.) from database inception through June 2020. We reviewed the bibliographies of systematic reviews and other relevant articles, and contacted experts to identify additional studies. To identify unpublished literature, we searched the VHA Health Services Research and Development website, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform. Search strategies were developed in consultation with a research librarian and peer reviewed by another research librarian using the instrument for Peer Review of Search Strategies (see Supplemental Appendix 1) (18).

Study Selection

Studies were eligible if they (1) included adults with dialysis-dependent ESKD not slated for transplant and depression, defined by established thresholds for chronically ill populations (19⇓⇓⇓–23); (2) directly compared any pharmacologic or nonpharmacologic treatments for depression to placebo, wait-list control, or other intervention; (3) were randomized controlled trials (RCTs) or nonrandomized controlled trials in any setting (for harms outcomes, we also included observational studies); (4) assessed patient outcomes of interest (e.g., depression symptom severity, suicidal ideation, QoL); and (5) were published in English. We excluded studies examining adults with AKI or those with CKD stages 1–4. See Supplemental Appendix 2 and Supplemental Table 1 for complete selection criteria. All studies were reviewed for inclusion by two independent reviewers at the title/abstract and full-text levels. Discords were resolved through consensus or consultation with a third reviewer.

Data Abstraction and Quality Assessment

From included studies, we abstracted details on study design, sample size, setting, population characteristics, participant selection criteria, and intervention details (including the dosage, timing, and administration methods; duration of treatment and follow-up; outcomes; and relevant harms). Data from studies meeting inclusion criteria were abstracted by one reviewer and confirmed by an additional reviewer.

Two reviewers independently assessed the methodologic quality of each study using criteria established by the US Preventive Services Taskforce and adapted for depression interventions (24⇓–26). Disagreements were resolved by consensus or a third reviewer.

Data Synthesis and Analysis

We qualitatively synthesized the evidence for each treatment category and outcome of interest. We were unable to quantitatively synthesize the evidence because there were too few studies examining the same intervention and reporting the same outcome measure (52).

Using an established method by Berkman et al. (53), for each intervention, we assessed the overall strength of evidence (SOE) that considers study limitations, directness, consistency, precision, and reporting bias to classify the SOE for each outcome independently as high, moderate, low, or insufficient; we used separate guidance for the applicability (external validity) of the evidence to the clinical question (54). Supplemental Table 2 describes SOE domains and grading in more detail.

Results

We reviewed 8050 titles and abstracts, 192 of which qualified for full-text review. Of those, we included a total of 26 RCTs; nine examined pharmacologic interventions and 17 examined nonpharmacologic interventions for the treatment of depression in adults with ESKD. We also included three observational studies reporting harms of selective serotonin reuptake inhibitors (SSRIs; see Figure 1 for literature flow, and Table 1 for study characteristics).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The flow diagram of the literature-review process shows 26 RCTs and 3 observational studies. *After deduplication. CDSR, Cochrane Database of Systematic Reviews; DARE, Database of Abstracts of Reviews of Effects; EBM, Evidence-Based Medicine; HSR&D, Health Services Research and Development Service; HTA, Health Technology Assessment; RCTs, randomized controlled trials; VA, Veterans Affairs; WHO ICTRP, World Health Organization International Clinical Trials Registry Platform.

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of randomized controlled trials of interventions for depression and studies examining harms of depression treatment in adults with ESKD

Pharmacologic Treatments

SSRIs

SSRIs versus Placebo

Three studies comparing SSRIs with placebo report conflicting findings and provide insufficient evidence to draw conclusions about their effectiveness in treating depression in adults with ESKD (see Table 2 for study results and Table 3 for SOE ratings). Two small US RCTs (one 8-week, poor-quality trial of fluoxetine [N=14] [30], and one recent, fair-quality, 6-month trial of sertraline [A Study of Sertraline in Dialysis; ASSertID; N=30] [33]) found no difference in depressive-symptom reduction between those assigned to SSRIs or placebo. One fair-quality, 12-week, Iranian RCT (N=50) (46) found that participants who received sertraline reported a significant reduction in depressive symptoms compared with placebo. Small sample sizes and differences in depression assessment tools and statistical analyses detracted from the quality of these studies (see Table 4 for quality ratings).

View this table:
  • View inline
  • View popup
Table 2.

Efficacy of interventions from randomized controlled trials for depression in adults with ESKD

View this table:
  • View inline
  • View popup
Table 3.

Summary of the evidence on interventions for depression in adults with ESKD

View this table:
  • View inline
  • View popup
Table 4.

Quality and applicability assessment of randomized controlled trials

SSRIs versus Active Comparators
SSRIs versus CBT

A recent, fair-quality, multisite, head-to-head RCT (N=120) in the United States (A Trial of Sertraline versus Cognitive Behavioral Therapy for ESKD Adults with Depression; ASCEND [44]) provides low-strength evidence that sertraline and CBT are similar when used for the reduction of depressive symptoms (Tables 3 and 4). Over the 12-week study period, both groups improved significantly. Participants who received sertraline experienced significantly greater improvement (effect estimate, −1.85; 95% CI, −3.55 to −0.16; Table 2) when assessed by a clinician (Quick Inventory of Depressive Symptomatology). There was no difference between groups in self-reported symptoms (i.e., Beck Depression Inventory-II; effect estimate, −2.9; 95% CI, −6.7 to 0.8; Table 2).

SSRIs versus Psychologic Training

A small (N=44), 3-month, poor-quality RCT (38), conducted in Iran, provides insufficient evidence for the comparison of citalopram to “psychologic training” in participants with ESKD and depression (Tables 3 and 4). Although both arms reported a reduction in depressive symptoms, there was no difference between groups (Table 2).

Harms of SSRIs

Adverse events (AEs) reported in the included trials of SSRIs in adults with depression and ESKD were similar in type and frequency to those reported by the general population on SSRIs (59). One trial reported a higher rate of dropout due to AEs associated with sertraline (33% versus 0%; P=0.04) (33). Across all four trials (30,33,44,46), a wide range of AEs (e.g., nausea, headaches, dizziness) were reported by participants in both treatment and control groups, but they were not consistently nor uniformly reported (Table 5).

View this table:
  • View inline
  • View popup
Table 5.

Adverse events reported in depression treatment trials in patients with ESKD

Additionally, three observational studies focused specifically on potential harms related to SSRIs in adults with ESKD and depression (Table 6). Two examined Medicare beneficiaries who received SSRIs that were included in the US Renal Data System registry. A case-control study (N=54,032) found that SSRIs increased the risk of hip fracture regardless of dose or duration (58), and the second (57), a retrospective cohort study (N=65,654), found that adults, especially older adults and women, taking SSRIs with higher QT-prolonging potential (i.e., citalopram and escitalopram) were at higher risk for sudden cardiac death (adjusted hazard ratio, 1.18; 95% CI, 1.05 to 1.31). The final study was a follow-up to the ASSertID RCT (33) that examined SSRI practice patterns in adults with ESKD, and included participants who were already on SSRIs at baseline (N=41). Findings suggest poor medication management and both under- and over-treatment (56).

View this table:
  • View inline
  • View popup
Table 6.

Adverse events reported in observational studies of adults with ESKD and depression

Supplements versus Placebo

High-dose Vitamin D3

A large (N=746), fair-quality, 52-week RCT (50) provides moderate-strength evidence that long-term, high-dose vitamin D3 does not reduce depression severity in adults with ESKD (Tables 3 and 4). In addition, no differences were reported by age, sex, body mass index, or plasma albumin level. Although overall differences in depressive-symptom reduction between groups were NS, a subgroup of participants with vascular depression (but not those with major depressive disorder) receiving vitamin D3 did report significantly greater reduction in depressive symptoms at 1 year (Table 2).

Harms of Vitamin D3

AEs associated with high-dose vitamin D3, including joint pain, diarrhea, nausea, and vomiting, resulted in study withdrawal of five participants. No statistical analyses of AEs or withdrawals due to AEs were reported (50).

Ω-3 Fatty Acids

A single, poor-quality RCT (N=54) (35), conducted in Iran, provides insufficient evidence to form conclusions about the effect of Ω-3 fatty acids versus placebo on depression severity in adults with ESKD (Tables 3 and 4). At 16 weeks, the Ω-3 fatty acids group reported a significantly greater reduction in depressive symptoms compared with both placebo and their own baseline. No differences were identified by age, sex, baseline depression severity, or length of time on hemodialysis (Table 2). No serious AEs (SAEs) were reported in this trial.

Synbiotic and Probiotic Supplements

One good-quality, 12-week RCT (N=49) (36) provides insufficient evidence for the use of synbiotic or probiotic supplements versus placebo on depression severity in Iranian adults with ESKD and Hospital Anxiety and Depression Scale–Depression (HADS-D) scores of eight or higher (Tables 3 and 4). HADS-D scores at the end of treatment were significantly lower in adults receiving synbiotics than those receiving placebo (P<0.001) and probiotics (P=0.01). HADS-D scores were also significantly reduced from baseline in the symbiotic compared with placebo (P<0.001) groups, but not in the other comparisons (Table 2). The reported AEs were few and mild (Table 5).

Radix Bupleuri Herbal Supplement

A poor-quality, 3-month RCT (N=160) (49) of Radix Bupleuri root powder supplements compared with placebo provides insufficient evidence for its use for depression in adults with ESKD (Tables 3 and 4). Participants who were being treated with antidepressant medications (about half of each group) continued on those treatments concurrently during this trial. Participants taking Radix Bupleuri experienced significantly more reduction in Montgomery–Åsberg Depression Rating Scale scores compared with the placebo group (P=0.02; Table 2). They also experienced improvement in QoL (measured by RAND-36) compared with the placebo group (P=0.04). The trial did not report on AEs.

Nonpharmacologic Treatments

CBT

CBT versus Psychotherapy

One fair-quality RCT (N=90) (32) provides low-strength evidence that small-group CBT is more effective than brief, individualized psychotherapy for reducing depression severity in participants with ESKD (Tables 3 and 4). Depressive symptoms improved significantly in both groups. Participants receiving CBT also experienced a significant within-group decrease in suicide risk and improved on several QoL domains (i.e., burden of kidney disease, quality of social interaction, sleep, overall health, and mental health) over the study period (Table 2). No study dropouts from serious AEs were reported.

CBT versus Psychoeducation

A poor-quality RCT (27), conducted in Jordan, provides insufficient evidence to form conclusions about the comparison of CBT with psychoeducation (Tables 3 and 4). Participants receiving CBT reported a significantly greater reduction in depressive symptoms (both groups reported significant improvement; Table 2).

CBT versus Sertraline

A head-to-head RCT (44) provides low-strength evidence that sertraline and CBT are similar when used for the reduction of depressive symptoms in participants with depression and ESKD. See the section SSRIs versus CBT above and Tables 2⇑–4 for more detail.

CBT versus Control

Two fair-quality RCTs (31,41) provide low-strength evidence that CBT is more effective than wait-list control for reducing depression severity and improving QoL in participants with ESKD (Tables 3 and 4). There is insufficient evidence to form conclusions about the benefit of CBT on fluid adherence (31).

One study compared outcomes (depressive symptoms, QoL, and fluid adherence) on the basis of the timing of the intervention (treatment first or after 90-day wait listing). Results indicated that participants receiving CBT experienced significantly greater benefit across all outcomes in both phases. However, findings suggest a sequence effect for depressive-symptom reduction (the treatment-first group experienced greater benefit than the wait-list group), but none for QoL or fluid compliance (Table 2) (31).

Acupressure

We found low-strength evidence that acupressure is more effective than both usual care and sham acupressure for reducing depression severity in participants with ESKD (Table 3). There is insufficient evidence to form conclusions about the comparison of acupressure to transcutaneous electrical acupoint stimulation (TEAS) for the reduction of depressive-symptom severity, fatigue, or sleep-quality improvement. A fair-quality, three-arm RCT (N=96) (39) compared acupressure with sham acupressure (i.e., pressure applied 1 cm from the acupressure point) and usual care. Participants receiving acupressure reported a significantly greater reduction in depression symptoms than those receiving sham acupressure or usual care (there was no difference between sham and usual care). A second three-arm RCT (poor quality; N=108) (48) compared acupressure with both TEAS and usual care. Participants in both the acupressure and the TEAS groups reported greater reductions in depressive symptoms and fatigue, and better-quality sleep than those who received usual care (Tables 2 and 4).

Intensive Nursing

Three poor-quality RCTs (42,43,55) provide insufficient evidence for the effect of intensive nursing interventions, compared with less-intensive nursing, for improving depressive symptoms in adults with ESKD (Tables 3 and 4). One study in China (N=72) compared home-nursing visits with telephone follow-up for adults on peritoneal dialysis (42). Although both groups’ Zung Self-Rating Depression Scale scores were improved from baseline (P<0.001), the home-nursing group’s depression scores were significantly lower than the control group after intervention (P<0.001). Another Chinese study of a comprehensive nursing intervention compared with usual care (N=128) (43) in adults on hemodialysis found that the intervention group had significantly greater reduction in Self-Rating Depression Scale scores from baseline (P=0.04), and those scores were significantly better after intervention compared with the control group (P=0.05). An Iranian RCT (N=60) using the Depression, Anxiety, and Stress Scale found that telenursing follow-ups compared with usual care (no telephone follow-ups) resulted in significantly lower depression scores (Table 2) (55). These studies did not report on AEs.

Exercise

There was insufficient evidence from two poor-quality studies (34,40) on exercise training for depression in adults with ESKD (Tables 3 and 4). One study (N=50) (34) examined the effect of 4 months of endurance and resistance training four times weekly in Tunisian male participants. Training sessions were on off-dialysis days and the exercise group significantly improved on HADS-D scores compared with sedentary controls. The other, a Greek RCT (N=50) (40), examined intradialytic exercise (during hemodialysis cycling and strength training) three times per week for a year and found significant improvement on both the Beck Depression Inventory-II and HADS-D with exercise compared with sedentary controls (Table 2). AEs were not reported.

Other Treatments

We included RCTs of six other therapies: Benson relaxation technique (37), guided imagery (29), hope therapy (45), Latihan Pasrah Diri (51), mindfulness-based stress reduction (47), and Quran readings for Muslim participants (28). All were small, single trials with methodologic challenges, and the evidence is insufficient for all interventions (Tables 2⇑–4). Two of these studies (Latihan Pasrah Diri [51] and mindfulness-based stress reduction [47]) reported no AEs, whereas the others did not report on AEs.

Discussion

In this systematic review, we examined nine RCTs of pharmacologic interventions and 17 of nonpharmacologic interventions for comorbid depression in adults with ESKD. We also found three observational studies that contributed to the evidence on harms of SSRIs. We found moderate-strength evidence that long-term, high-dose vitamin D3 is ineffective for reducing depressive symptoms, and low-strength evidence that both sertraline and CBT were similar for improving depressive symptoms. We also found low-strength evidence that CBT is more effective than both standard psychotherapy and wait-list controls, and that acupressure is more effective than usual care. We found insufficient evidence to draw conclusions about all other interventions. Overall, we found limited evidence for each intervention, sample sizes were small, and nearly all studies were hampered by methodologic flaws.

SSRIs, compared either with placebo or an active comparator, were the best-studied pharmacologic intervention. No other antidepressant categories were identified. Findings from placebo-controlled trials of SSRIs were mixed, but sertraline at least warrants further study. Among the three trials examining sertraline, one reported benefit over placebo, and another found no difference between sertraline and CBT (44). Harms related to SSRIs were not uniformly reported. The type and rate of harms reported and/or evaluated in included RCTs suggest little to no increase in risk for adults with ESKD compared with otherwise healthy adults using SSRIs. Primary side effects were minor (e.g., nausea, fatigue). However, observational studies suggest that clinicians should consider known risks (e.g., QT prolongation) when making prescribing decisions, and to coordinate care to avoid over- or under-treatment.

Vitamin D3 is an interesting intervention for adults with ESKD, due to the associated risks of hypercalcemia and hyperphosphatemia (60). Five adults withdrew from the study due to treatment-related AEs. Although not attributed to hyperphosphatemia, the reported AEs (i.e., joint pain, diarrhea, nausea, and vomiting) may be related. The negative finding regarding vitamin D3, along with its risks, suggests that clinicians should not recommend its use as a depression treatment in this population. Given the large size and length of the trial, the SOE for this finding is moderate, and future studies are unlikely to change conclusions.

Very few nonpharmacologic studies reported harms; however, most interventions presented minimal risk. Differences by subpopulation (i.e., demographic, clinical) were also reported in very few studies, and reported differences were insufficient to form conclusions. Future research should uniformly report harms and examine these subgroups.

Many of the studies were hampered by small sample sizes, posing challenges related to group comparability and statistical power. The duration of treatment and follow-up varied widely across studies, making it more challenging to compare results. For instance, between two studies of sertraline, one was twice as long as the other (3 versus 6 months). The methods used to screen for and diagnose depression were heterogeneous, as was the implementation of interventions (e.g., timing, doses, comparators, modes of delivery). For example, among CBT studies, although all of them met in person, half of the studies used private sessions, and sessions were conducted in groups in the other studies. Session lengths varied and, in one study, CBT was delivered while the participants were receiving hemodialysis. Given the association with hemodialysis and somatic complaints, hemodynamic changes, and alterations in mental acuity, treatments (particularly psychologic ones) that are administered during hemodialysis may be confronted with these challenges; although treating adults outside of hemodialysis sessions has its own challenges, including the increased time burden and physical and mental fatigue. Among other psychologic treatments, some were applied in person, whereas others were practices expected to be followed at home. In addition to these issues, the lack of methodologic detail reported in many of the studies resulted in poor-quality ratings and uncertainty about study processes.

Another important limitation to the current evidence base is that most of the studies were conducted outside of the United States and examined participants and health systems that differ greatly from the general US population. These differences may be reflected in both the patient demographics and medical disease burden, and in how care is delivered, particularly because the majority of US adults on dialysis receive their care from large dialysis organizations in coordination with their nephrology provider.

This is the only systematic review to date that examines both pharmacologic and nonpharmacologic treatment of depression in adults with ESKD. This review confirms and adds to a 2016 Cochrane review of antidepressants in adults with ESKD, which included meta-analyses of harms reported in trials included in our report (59). Although we also included more recent trials, outcomes were not reported in a way that allowed for a quantitative synthesis of harms. Our review adds to the pharmacologic evidence by including studies of dietary supplements. A Cochrane review examining psychosocial interventions for adults with ESKD was recently published (61); however, it includes studies of participants with and without clinical depression. How a participant with ESKD responds to an intervention may vary widely depending on the severity of their baseline depressive symptoms. To reduce clinical heterogeneity, we included only studies with participants meeting established depression-screening thresholds for chronically ill populations (19⇓⇓⇓–23). Finally, additional trials included in our review, particularly the ASCEND (44) and ASSertID trials (33,44), add to both the pharmacologic and nonpharmacologic evidence.

Future research, particularly in the United States, is needed to better evaluate both pharmacologic and nonpharmacologic interventions for this population. In particular, larger replication studies of CBT, acupressure, and SSRIs (such as sertraline), and examination of their effects in different subgroups of adults with ESKD and depression (such as severity of depression, duration of ESKD diagnosis, peritoneal versus hemodialysis, and presence of comorbidities), will help decision makers to implement depression treatments that are not only evidence based, but are also the best fit for their patient population.

Disclosures

All authors have nothing to disclose.

Funding

This research was funded by the US Department of Veterans Affairs, VHA, Office of Research and Development, Health Services Research and Development.

Supplemental Material

This article contains supplemental material online at http://kidney360.asnjournals.org/lookup/suppl/doi:10.34067/KID.0003142020/-/DCSupplemental.

Supplemental Appendix 1. Search strategies (parent VA review).

Supplemental Appendix 2. Study selection criteria (parent VA review).

Supplemental Table 1. PICOTS by key question.

Supplemental Table 2. Strength of evidence domains and grading.

Acknowledgments

The authors wish to thank Ms. Robin Paynter (MLIS) for developing the search strategy and running electronic searches. We also thank the members of our technical expert panel for their expertise.

The findings and conclusions in this document are those of the authors who are responsible for its contents, the findings and conclusions do not necessarily represent the views of the Department of Veterans Affairs or the US Government.

Each author contributed important intellectual content during manuscript drafting or revision, accepts personal accountability for the author’s own contributions, and agrees to ensure that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Author Contributions

J.R. Antick, D. Kansagara, and K. Kondo provided supervision; C.K. Ayers was responsible for project administration; C.K. Ayers, P. Chopra, D. Kansagara, and K. Kondo reviewed and edited the manuscript; C.K. Ayers, P. Chopra, and K. Kondo were responsible for investigation; C.K. Ayers and K. Kondo were responsible for data curation and methodology; and all authors conceptualized the study, were responsible for formal analysis, and wrote the original draft.

  • Received May 19, 2020.
  • Accepted January 4, 2021.
  • Copyright © 2021 by the American Society of Nephrology

References

  1. ↵
    1. United States Renal Data System
    , USRDS Annual Data Report United States Renal Data System 2018 Available at: https://www.usrds.org/media/2283/2018_volume_2_esrd_in_the_us.pdf. Accessed April 20, 2019
  2. ↵
    1. Fukunishi I,
    2. Kitaoka T,
    3. Shirai T,
    4. Kino K,
    5. Kanematsu E,
    6. Sato Y
    : Psychiatric disorders among patients undergoing hemodialysis therapy. Nephron 91: 344–347, 2002 https://doi.org/10.1159/000058418
    OpenUrlCrossRefPubMed
  3. ↵
    1. Kimmel PL,
    2. Thamer M,
    3. Richard CM,
    4. Ray NF
    : Psychiatric illness in patients with end-stage renal disease. Am J Med 105: 214–221, 1998 https://doi.org/10.1016/S0002-9343(98)00245-9
    OpenUrlCrossRefPubMed
  4. ↵
    1. De Sousa A
    : Psychiatric issues in renal failure and dialysis. Indian J Nephrol 18: 47–50, 2008 https://doi.org/10.4103/0971-4065.42337
    OpenUrlCrossRefPubMed
  5. ↵
    National Institute of Mental Health: Major depression. Available at: https://www.nimh.nih.gov/health/statistics/major-depression.shtml. Accessed October 31, 2019
  6. ↵
    1. Palmer S,
    2. Vecchio M,
    3. Craig JC,
    4. Tonelli M,
    5. Johnson DW,
    6. Nicolucci A,
    7. Pellegrini F,
    8. Saglimbene V,
    9. Logroscino G,
    10. Fishbane S,
    11. Strippoli GF
    : Prevalence of depression in chronic kidney disease: Systematic review and meta-analysis of observational studies. Kidney Int 84: 179–191, 2013 https://doi.org/10.1038/ki.2013.77
    OpenUrlCrossRefPubMed
  7. ↵
    1. Lacson E Jr.,
    2. Bruce L,
    3. Li NC,
    4. Mooney A,
    5. Maddux FW
    : Depressive affect and hospitalization risk in incident hemodialysis patients. Clin J Am Soc Nephrol 9: 1713–1719, 2014 https://doi.org/10.2215/CJN.01340214
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Farrokhi F,
    2. Abedi N,
    3. Beyene J,
    4. Kurdyak P,
    5. Jassal SV
    : Association between depression and mortality in patients receiving long-term dialysis: A systematic review and meta-analysis. Am J Kidney Dis 63: 623–635, 2014 https://doi.org/10.1053/j.ajkd.2013.08.024
    OpenUrlCrossRefPubMed
  9. ↵
    1. Xing L,
    2. Chen R,
    3. Diao Y,
    4. Qian J,
    5. You C,
    6. Jiang X
    : Do psychological interventions reduce depression in hemodialysis patients?: A meta-analysis of randomized controlled trials following PRISMA. Medicine (Baltimore) 95: e4675, 2016 https://doi.org/10.1097/MD.0000000000004675
    OpenUrlPubMed
  10. ↵
    1. Weisbord SD,
    2. Mor MK,
    3. Sevick MA,
    4. Shields AM,
    5. Rollman BL,
    6. Palevsky PM,
    7. Arnold RM,
    8. Green JA,
    9. Fine MJ
    : Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis. Clin J Am Soc Nephrol 9: 1594–1602, 2014 https://doi.org/10.2215/CJN.00220114
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Kurella M,
    2. Kimmel PL,
    3. Young BS,
    4. Chertow GM
    : Suicide in the United States end-stage renal disease program. J Am Soc Nephrol 16: 774–781, 2005 https://doi.org/10.1681/ASN.2004070550
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Watnick S,
    2. Kirwin P,
    3. Mahnensmith R,
    4. Concato J
    : The prevalence and treatment of depression among patients starting dialysis. Am J Kidney Dis 41: 105–110, 2003 https://doi.org/10.1053/ajkd.2003.50029
    OpenUrlCrossRefPubMed
  13. ↵
    1. Kimmel PL,
    2. Peterson RA,
    3. Weihs KL,
    4. Simmens SJ,
    5. Alleyne S,
    6. Cruz I,
    7. Veis JH
    : Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients. Kidney Int 54: 245–254, 1998 https://doi.org/10.1046/j.1523-1755.1998.00989.x
    OpenUrlCrossRefPubMed
  14. ↵
    1. Sullivan JE,
    2. Choi NG,
    3. Vazquez CE,
    4. Neaves MA
    : Psychosocial depression interventions for dialysis patients, with attention to Latinos: A scoping review. Res Soc Work Pract 29: 910–923, 2019 https://doi.org/10.1177/1049731518820134
    OpenUrl
  15. ↵
    1. Shirazian S,
    2. Grant CD,
    3. Aina O,
    4. Mattana J,
    5. Khorassani F,
    6. Ricardo AC
    : Depression in chronic kidney disease and end-stage renal disease: Similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep 2: 94–107, 2016 https://doi.org/10.1016/j.ekir.2016.09.005
    OpenUrl
  16. ↵
    1. Kondo K,
    2. Ayers CK,
    3. Chopra P,
    4. Antick J,
    5. Kansagara D
    : End Stage Renal Disease and Depression: A Systematic Review. VA ESP Project #05-225. Washington, DC, Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs, 2020. Available at: https://www.hsrd.research.va.gov/publications/esp/esrd-depression.cfm. Accessed January 12, 2021
  17. ↵
    1. Moher D,
    2. Liberati A,
    3. Tetzlaff J,
    4. Altman DG
    ; The PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6: e1000097, 2009 10.1371/journal.pmed1000097
    OpenUrlCrossRefPubMed
  18. ↵
    1. McGowan J,
    2. Sampson M,
    3. Salzwedel DM,
    4. Cogo E,
    5. Foerster V,
    6. Lefebvre C
    : PRESS peer review of electronic search strategies: 2015 Guideline statement. J Clin Epidemiol 75: 40–46, 2016 https://doi.org/10.1016/j.jclinepi.2016.01.021
    OpenUrlCrossRefPubMed
  19. ↵
    Department of Veterans Affairs, Department of Defense: VA/DoD clinical practice guideline for the management of major depressive disorder. Version 3.0. Washington, D.C., Department of Veterans Affairs, Department of Defense,2016
  20. ↵
    Centers for Medicare and Medicaid Services Center for Clinical Standards & Quality: Summary of representative clinical depression screening tools. Centers for Medicare and Medicaid Services Center for Clinical Standards & Quality, 2015
  21. ↵
    1. Furukawa TA,
    2. Reijnders M,
    3. Kishimoto S,
    4. Sakata M,
    5. DeRubeis RJ,
    6. Dimidjian S,
    7. Dozois DJA,
    8. Hegerl U,
    9. Hollon SD,
    10. Jarrett RB,
    11. Lespérance F,
    12. Segal ZV,
    13. Mohr DC,
    14. Simons AD,
    15. Quilty LC,
    16. Reynolds CF,
    17. Gentili C,
    18. Leucht S,
    19. Engel RR,
    20. Cuijpers P
    : Translating the BDI and BDI-II into the HAMD and vice versa with equipercentile linking. Epidemiol Psychiatr Sci 29: e24, 2019 https://doi.org/10.1017/S2045796019000088
    OpenUrlPubMed
  22. ↵
    1. Stafford L,
    2. Berk M,
    3. Jackson HJ
    : Validity of the hospital anxiety and depression scale and patient health questionnaire-9 to screen for depression in patients with coronary artery disease. Gen Hosp Psychiatry 29: 417–424, 2007 https://doi.org/10.1016/j.genhosppsych.2007.06.005
    OpenUrlCrossRefPubMed
  23. ↵
    1. Cameron IM,
    2. Crawford JR,
    3. Lawton K,
    4. Sharma S,
    5. Dutoit S,
    6. Hay S,
    7. Reid IC
    ; Applied Health Sciences (Mental Health): Assessing the validity of the PHQ-9, HADS, BDI-II and QIDS-SR in measuring severity of depression in a UK sample of primary care patients with a diagnosis of depression: Study protocol. Primary Care and Community Psychiatry 13: 67–71, 2008
    OpenUrl
  24. ↵
    1. O’Connor E,
    2. Rossom RC,
    3. Henninger M,
    4. Groom HC,
    5. Burda BU,
    6. Henderson JT,
    7. Bigler KD,
    8. Whitlock EP
    : Screening for depression in adults: An updated systematic evidence review for the U.S. Preventive Services Task Force, Rockville, MD, Agency for Healthcare Research and Quality (US), 2016
  25. ↵
    1. US Preventive Services Task Force
    : Appendix VII. Criteria for assessing external validity (Generalizability) of individual studies, 2017. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/procedure-manual/procedure-manual-appendix-vii-criteria-assessing-external-validity-generalizability-individual-studies. Accessed November 1, 2019
  26. ↵
    US Preventive Services Task Force: Appendix VI. Criteria for assessing internal validity of individual studies, 2017. Available at: https://www.uspreventiveservicestaskforce.org/Page/Name/appendix-vi-criteria-for-assessing-internal-validity-of-individual-studies. Accessed November 1, 2019
  27. ↵
    1. Al Saraireh FA,
    2. Aloush SM,
    3. Al Azzam M,
    4. Al Bashtawy M
    : The effectiveness of cognitive behavioral therapy versus psychoeducation in the management of depression among patients undergoing haemodialysis. Issues Ment Health Nurs 39: 514–518, 2018 https://doi.org/10.1080/01612840.2017.1406022
    OpenUrl
  28. ↵
    1. Babamohamadi H,
    2. Sotodehasl N,
    3. Koenig HG,
    4. Al Zaben F,
    5. Jahani C,
    6. Ghorbani R
    : The effect of holy Qur’an recitation on depressive symptoms in hemodialysis patients: A randomized clinical trial. J Relig Health 56: 345–354, 2017 https://doi.org/10.1007/s10943-016-0281-0
    OpenUrl
  29. ↵
    1. Beizaee Y,
    2. Rejeh N,
    3. Heravi-Karimooi M,
    4. Tadrisi SD,
    5. Griffiths P,
    6. Vaismoradi M
    : The effect of guided imagery on anxiety, depression and vital signs in patients on hemodialysis. Complement Ther Clin Pract 33: 184–190, 2018 https://doi.org/10.1016/j.ctcp.2018.10.008
    OpenUrl
  30. ↵
    1. Blumenfield M,
    2. Levy NB,
    3. Spinowitz B,
    4. Charytan C,
    5. Beasley CM Jr.,
    6. Dubey AK,
    7. Solomon RJ,
    8. Todd R,
    9. Goodman A,
    10. Bergstrom RF
    : Fluoxetine in depressed patients on dialysis. Int J Psychiatry Med 27: 71–80, 1997 https://doi.org/10.2190/WQ33-M54T-XN7L-V8MX
    OpenUrlCrossRefPubMed
  31. ↵
    1. Cukor D,
    2. Ver Halen N,
    3. Asher DR,
    4. Coplan JD,
    5. Weedon J,
    6. Wyka KE,
    7. Saggi SJ,
    8. Kimmel PL
    : Psychosocial intervention improves depression, quality of life, and fluid adherence in hemodialysis. J Am Soc Nephrol 25: 196–206, 2014 https://doi.org/10.1681/ASN.2012111134
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Duarte PS,
    2. Miyazaki MC,
    3. Blay SL,
    4. Sesso R
    : Cognitive-behavioral group therapy is an effective treatment for major depression in hemodialysis patients. Kidney Int 76: 414–421, 2009 https://doi.org/10.1038/ki.2009.156
    OpenUrlCrossRefPubMed
  33. ↵
    1. Friedli K,
    2. Guirguis A,
    3. Almond M,
    4. Day C,
    5. Chilcot J,
    6. Da Silva-Gane M,
    7. Davenport A,
    8. Fineberg NA,
    9. Spencer B,
    10. Wellsted D,
    11. Farrington K
    : Sertraline versus placebo in patients with major depressive disorder undergoing hemodialysis: A randomized, controlled feasibility trial. Clin J Am Soc Nephrol 12: 280–286, 2017 https://doi.org/10.2215/CJN.02120216
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Frih B,
    2. Jaafar H,
    3. Mkacher W,
    4. Ben Salah Z,
    5. Hammami M,
    6. Frih A
    : The effect of interdialytic combined resistance and aerobic exercise training on health related outcomes in chronic hemodialysis patients: The Tunisian randomized controlled study. Front Physiol 8: 288, 2017 https://doi.org/10.3389/fphys.2017.00288
    OpenUrlPubMed
  35. ↵
    1. Gharekhani A,
    2. Khatami MR,
    3. Dashti-Khavidaki S,
    4. Razeghi E,
    5. Noorbala AA,
    6. Hashemi-Nazari SS,
    7. Mansournia MA
    : The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: A randomized, placebo-controlled clinical trial. Eur J Clin Pharmacol 70: 655–665, 2014 https://doi.org/10.1007/s00228-014-1666-1
    OpenUrl
  36. ↵
    1. Haghighat N,
    2. Rajabi S,
    3. Mohammadshahi M
    : Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: A randomized, double-blinded, clinical trial [published online ahead of print August 4, 2019]. Nutr Neurosci 10.1080/1028415X.2019.1646975
  37. ↵
    1. Heshmatifar N,
    2. Sadeghi H,
    3. Mahdavi A,
    4. Shegarf Nakhaie MR,
    5. Rakhshani MH
    : The effect of Benson relaxation technique on depression in patients undergoing hemodialysis. Majallah-i Danishgah-i Ulum-i Pizishki-i Babul 17: 34, 2015
    OpenUrl
  38. ↵
    1. Hosseini SH,
    2. Espahbodi F,
    3. Mirzadeh Goudarzi SM
    : Citalopram versus psychological training for depression and anxiety symptoms in hemodialysis patients. Iran J Kidney Dis 6: 446–451, 2012
    OpenUrlPubMed
  39. ↵
    1. Kalani L,
    2. Aghababaeian H,
    3. Majidipour N,
    4. Alasvand M,
    5. Bahrami H,
    6. Sabouhi F,
    7. Valiani M,
    8. Mortazavi M,
    9. Exir J
    : The effects of acupressure on severity of depression in hemodialysis patients: A randomized controlled trial. J Adv Pharm Educ Res 9: 67–72, 2019
    OpenUrl
  40. ↵
    1. Kouidi E,
    2. Karagiannis V,
    3. Grekas D,
    4. Iakovides A,
    5. Kaprinis G,
    6. Tourkantonis A,
    7. Deligiannis A
    : Depression, heart rate variability, and exercise training in dialysis patients. Eur J Cardiovasc Prev Rehabil 17: 160–167, 2010 https://doi.org/10.1097/HJR.0b013e32833188c4
    OpenUrlCrossRefPubMed
  41. ↵
    1. Lerma A,
    2. Perez-Grovas H,
    3. Bermudez L,
    4. Peralta-Pedrero ML,
    5. Robles-García R,
    6. Lerma C
    : Brief cognitive behavioural intervention for depression and anxiety symptoms improves quality of life in chronic haemodialysis patients. Psychol Psychother 90: 105–123, 2017 https://doi.org/10.1111/papt.12098
    OpenUrl
  42. ↵
    1. Li F,
    2. Han W,
    3. Chen W
    : The effects of continuous home nursing visits on patients with chronic renal failure and peritoneal dialysis. Int J Clin Exp Med 13: 540–548, 2020
    OpenUrl
  43. ↵
    1. Liao B,
    2. Zhao L,
    3. Peng Y,
    4. Chen J,
    5. Chen W,
    6. Wang X
    : Effect of comprehensive nursing intervention on negative emotion, quality of life and renal function of hemodialysis patients. Int J Clin Exp Med 13: 949–957, 2020
    OpenUrl
  44. ↵
    1. Mehrotra R,
    2. Cukor D,
    3. Unruh M,
    4. Rue T,
    5. Heagerty P,
    6. Cohen SD,
    7. Dember LM,
    8. Diaz-Linhart Y,
    9. Dubovsky A,
    10. Greene T,
    11. Grote N,
    12. Kutner N,
    13. Trivedi MH,
    14. Quinn DK,
    15. Ver Halen N,
    16. Weisbord SD,
    17. Young BA,
    18. Kimmel PL,
    19. Hedayati SS
    : Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis: A randomized clinical trial. Ann Intern Med 170: 369–379, 2019 https://doi.org/10.7326/M18-2229
    OpenUrl
  45. ↵
    1. Rahimipour M,
    2. Shahgholian N,
    3. Yazdani M
    : Effect of hope therapy on depression, anxiety, and stress among the patients undergoing hemodialysis. Iran J Nurs Midwifery Res 20: 694–699, 2015 https://doi.org/10.4103/1735-9066.170007
    OpenUrl
  46. ↵
    1. Taraz M,
    2. Khatami MR,
    3. Dashti-Khavidaki S,
    4. Akhonzadeh S,
    5. Noorbala AA,
    6. Ghaeli P,
    7. Taraz S
    : Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: Results of a randomized double-blind, placebo-controlled clinical trial. Int Immunopharmacol 17: 917–923, 2013 https://doi.org/10.1016/j.intimp.2013.09.020
    OpenUrlPubMed
  47. ↵
    1. Thomas Z,
    2. Novak M,
    3. Platas SGT,
    4. Gautier M,
    5. Holgin AP,
    6. Fox R,
    7. Segal M,
    8. Looper KJ,
    9. Lipman M,
    10. Selchen S,
    11. Mucsi I,
    12. Herrmann N,
    13. Rej S
    : Brief mindfulness meditation for depression and anxiety symptoms in patients undergoing hemodialysis: A pilot feasibility study. Clin J Am Soc Nephrol 12: 2008–2015, 2017 https://doi.org/10.2215/CJN.03900417
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Tsay S-L,
    2. Cho Y-C,
    3. Chen M-L
    : Acupressure and Transcutaneous Electrical Acupoint Stimulation in improving fatigue, sleep quality and depression in hemodialysis patients. Am J Chin Med 32: 407–416, 2004 https://doi.org/10.1142/S0192415X04002065
    OpenUrlCrossRefPubMed
  49. ↵
    1. Wang X,
    2. Feng Q,
    3. Xiao Y,
    4. Li P
    : Radix Bupleuri ameliorates depression by increasing nerve growth factor and brain-derived neurotrophic factor. Int J Clin Exp Med 8: 9205–9217, 2015
    OpenUrl
  50. ↵
    1. Wang Y,
    2. Liu Y,
    3. Lian Y,
    4. Li N,
    5. Liu H,
    6. Li G
    : Efficacy of high-dose supplementation with oral vitamin D3 on depressive symptoms in dialysis patients with vitamin D3 insufficiency: A prospective, randomized, double-blind study. J Clin Psychopharmacol 36: 229–235, 2016 https://doi.org/10.1097/JCP.0000000000000486
    OpenUrl
  51. ↵
    1. Widyaningrum SA,
    2. Djarwoto B
    : Effects of Latihan Pasrah Diri in quality of life in chronic kidney disease-dialysis patients with depression symptoms. J Intern Med 3: 16–22, 2013
    OpenUrl
  52. ↵
    1. Lowry R
    : Predictive values and likelihood ratios. VassarStats: Website for statistical Computation. Available at: http://vassarstats.net/clin2.html. Accessed November 1, 2019
  53. ↵
    1. Berkman ND,
    2. Lohr KN,
    3. Ansari MT,
    4. Balk EM,
    5. Kane R,
    6. McDonagh M,
    7. Morton SC,
    8. Viswanathan M,
    9. Bass EB,
    10. Butler M,
    11. Gartlehner G,
    12. Hartling L,
    13. McPheeters M,
    14. Morgan LC,
    15. Reston J,
    16. Sista P,
    17. Whitlock E,
    18. Chang S
    : Grading the strength of a body of evidence when assessing health care interventions: An EPC update. J Clin Epidemiol 68: 1312–1324, 2015 https://doi.org/10.1016/j.jclinepi.2014.11.023
    OpenUrlCrossRefPubMed
  54. ↵
    1. Atkins D,
    2. Chang SM,
    3. Gartlehner G,
    4. Buckley DI,
    5. Whitlock EP,
    6. Berliner E,
    7. Matchar D
    : Assessing applicability when comparing medical interventions: AHRQ and the effective health care program. J Clin Epidemiol 64: 1198–1207, 2011 https://doi.org/10.1016/j.jclinepi.2010.11.021
    OpenUrlCrossRefPubMed
  55. ↵
    1. Kargar Jahromi M,
    2. Javadpour S,
    3. Taheri L,
    4. Poorgholami F
    : Effect of nurse-led telephone follow ups (Tele-Nursing) on depression, anxiety and stress in hemodialysis patients. Glob J Health Sci 8: 168–173, 2015 https://doi.org/10.5539/gjhs.v8n3p168
    OpenUrl
  56. ↵
    1. Guirguis A,
    2. Chilcot J,
    3. Almond M,
    4. Davenport A,
    5. Wellsted D,
    6. Farrington K
    : Antidepressant usage in haemodialysis patients: Evidence of sub-optimal practice patterns. J Ren Care 46: 124–132, 2020 https://doi.org/10.1111/jorc.12320
    OpenUrl
  57. ↵
    1. Assimon MM,
    2. Brookhart MA,
    3. Flythe JE
    : Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis. J Am Soc Nephrol 30: 611–623, 2019 https://doi.org/10.1681/ASN.2018101032
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Vangala C,
    2. Niu J,
    3. Montez-Rath ME,
    4. Yan J,
    5. Navaneethan SD,
    6. Winkelmayer WC
    : Selective serotonin reuptake inhibitor use and hip fracture risk among patients on hemodialysis. Am J Kidney Dis 75: 351–360, 2020 https://doi.org/10.1053/j.ajkd.2019.07.015
    OpenUrlPubMed
  59. ↵
    1. Palmer SC,
    2. Natale P,
    3. Ruospo M,
    4. Saglimbene VM,
    5. Rabindranath KS,
    6. Craig JC,
    7. Strippoli GF
    : Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis. Cochrane Database Syst Rev (5): CD004541, 2016 10.1002/14651858.CD004541.pub3
  60. ↵
    1. Covic A,
    2. Rastogi A
    : Hyperphosphatemia in patients with ESRD: Assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol 14: 153, 2013 https://doi.org/10.1186/1471-2369-14-153
    OpenUrl
  61. ↵
    1. Natale P,
    2. Palmer SC,
    3. Ruospo M,
    4. Saglimbene VM,
    5. Rabindranath KS,
    6. Strippoli GF
    : Psychosocial interventions for preventing and treating depression in dialysis patients. Cochrane Database of Syst Rev 12: CD004542, 2019 https://doi.org/10.1002/14651858.CD004542.pub3
    OpenUrl
View Abstract
PreviousNext
Back to top

In this issue

Kidney360: 2 (3)
Kidney360
Vol. 2, Issue 3
25 Mar 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article

Thank you for your interest in spreading the word on American Society of Nephrology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Effectiveness of Depression Treatment for Adults with ESKD: A Systematic Review
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Effectiveness of Depression Treatment for Adults with ESKD: A Systematic Review
Pavan Chopra, Chelsea K. Ayers, Jennifer R. Antick, Devan Kansagara, Karli Kondo
Kidney360 Mar 2021, 2 (3) 558-585; DOI: 10.34067/KID.0003142020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
The Effectiveness of Depression Treatment for Adults with ESKD: A Systematic Review
Pavan Chopra, Chelsea K. Ayers, Jennifer R. Antick, Devan Kansagara, Karli Kondo
Kidney360 Mar 2021, 2 (3) 558-585; DOI: 10.34067/KID.0003142020
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Supplemental Material
    • Acknowledgments
    • Author Contributions
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Biomarkers in ANCA-Associated Vasculitis: Potential Pitfalls and Future Prospects
  • Improving on the Adrogué–Madias Formula
Show more Review Articles

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Google Scholar

Keywords

  • clinical nephrology
  • depression
  • depression treatment
  • ESKD
  • ESRD
  • systematic review

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • Kidney360
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About Kidney360
  • Kidney360 Email Alerts
  • Kidney360 Podcasts
  • Kidney360 RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Disqus Code of Conduct
  • Disqus Information
  • Feedback
  • Follow on Twitter
  • Subscribe to JASN and CJASN

© 2021 American Society of Nephrology

Online ISSN - 2641-7650

Powered by HighWire